

Press Release
November 12, 2021

Scandion Oncology announce cancellation of extraordinary general meeting

Scandion Oncology A/S, today announced that the extraordinary general meeting on Wednesday November 17, 2021, has been cancelled.

The contemplated extraordinary general meeting in the Company on November 17, 2021 was initially requested by shareholders representing 5.71% of the registered share capital. The Board of Directors has now been informed that the request for an extraordinary general meeting with the proposed agenda is no longer supported by shareholders representing at least 5% of the registered share capital. For that reason, the planned extraordinary general meeting is cancelled.

The Board of Directors is currently evaluating the possibility to establish warrants for existing shareholders and will return shortly with a new notice for an extraordinary general meeting if the assessment result in a proposal that can be recommended by the Board of Directors.

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
E-mail: info@scandiononcology.com
Website: www.scandiononcology.com

Peter Høngaard Andersen, Chairman of the Board
Phone : +45 6190 5010
E-mail: info@scandiononcology.com
Website: www.scandiononcology.com

The information was submitted for publication, through the agency of the contact person set out above, on November 12, 2021, at 08:30 CET

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. **Ticker: SCOL.**

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.